Fmr LLC Purchases 23,436 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Fmr LLC raised its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,836,040 shares of the company’s stock after buying an additional 23,436 shares during the period. Fmr LLC owned about 9.67% of Immunocore worth $150,546,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Alpha DNA Investment Management LLC purchased a new position in Immunocore during the 3rd quarter valued at $411,000. HealthInvest Partners AB boosted its stake in shares of Immunocore by 127.4% during the third quarter. HealthInvest Partners AB now owns 54,060 shares of the company’s stock valued at $1,683,000 after purchasing an additional 30,282 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Immunocore by 27.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 498,221 shares of the company’s stock valued at $15,510,000 after purchasing an additional 107,656 shares during the period. Primecap Management Co. CA increased its stake in Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after buying an additional 520,950 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Immunocore by 7.5% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company’s stock valued at $13,297,000 after buying an additional 29,689 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Down 0.8 %

Shares of Immunocore stock opened at $32.22 on Wednesday. Immunocore Holdings plc has a 52-week low of $29.72 and a 52-week high of $76.98. The firm’s 50 day moving average price is $32.27 and its 200-day moving average price is $36.18. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The company has a market cap of $1.61 billion, a P/E ratio of -33.92 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.59) earnings per share. On average, sell-side analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on IMCR shares. Oppenheimer restated an “outperform” rating and issued a $89.00 target price (up from $87.00) on shares of Immunocore in a research note on Friday, August 9th. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $72.00 to $38.00 in a report on Monday, November 11th. Morgan Stanley lowered their target price on Immunocore from $80.00 to $74.00 and set an “overweight” rating for the company in a report on Friday, October 11th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Thursday, October 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Immunocore has an average rating of “Moderate Buy” and an average price target of $69.18.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.